Well this is mostly the same person, we know you love Alexion Chris thanks.
Now go drink yourself into passing out, it is what you do best. Hard to believe the company keeps a VP who has so many drunk questionable transgressions.
If the OP is serious the company is fine, do your diligence. The company is built on one drug with multiple indications. No pipeline to speak of that is public, 1210 is an extension of ecu. When the competition comes, the the market for a $500,000.00 drug will shrink. Insurance will demand patients fail a less expensive therapy first. But the best advice is to not use Cafepharma to make decisions about your future.